While in theory there could exist many such oncogenic aberrations in a pathway, the finding that the identified mutual exclusivity among AR, HOXC6 and NKX2-2 was preserved across a diverse collection of cancers provided strong evidence that aberrations in TF-based drivers, similar to their counter parts in signalling pathways, are limited to a core set of drivers in a parsimony fashion. The gene discussed is HOXC6; the disease is cancer.